Skip to main content
APhA DrugInfoLine
Sign in to your APhA membership account
Download a PDF of this month's content | Download a PDF of last month's content |Advanced Search
  • HOME
  • NEURO/PSYCH
    • Neurology
    • Psychiatry
  • HEART/LUNGS
    • Cardiology
    • Focus on Lipids Care
    • Focus on Anticoagulation Care
    • Respiratory
    • Focus on Asthma Care
  • GI/KIDNEYS
    • Gastroenterology
    • Nephrology
  • ENDOCRINE/RHEUM
    • Endocrinology
    • Focus on Diabetes Care
    • Rheumatology
  • ID/CANCERS
    • Infectious Diseases
    • Focus on HIV Care
    • Focus on Immunizations
    • Oncology
  • SELF-CARE
    • Alternative Medicines Corner
    • OTC Medicines Corner
  • PERSONALIZED CARE
    • Drug Interactions Corner
    • Pharmacogenomics Corner
  • Heart/Lungs
    Focus on Asthma Care...
    December 2, 2019

    As-needed corticosteroid–beta-agonist inhalers for adults with mild to moderate asthma?

    READ
  • Heart/Lungs
    Cardiology...
    December 2, 2019

    Survey suggests overuse of aspirin for primary prevention of CVD

    READ
  • Heart/Lungs
    Focus on Asthma Care...
    November 26, 2019

    Triple therapy in a single inhaler improves asthma symptoms and...

    READ
  • Self-care
    OTC Medicines Corner...
    November 26, 2019

    Analysis suggests OTC oral contraceptives may improve access,...

    READ
  • Endocrine/Rheum
    Rheumatology...
    November 18, 2019

    Non-TNFi biologics may be more effective than TNFis for...

    READ
  • ID/Cancers
    Focus on Immunizations...
    November 18, 2019

    CDC publishes updated HPV vaccination recommendations for adults

    READ
  • Heart/Lungs
    Cardiology...
    November 12, 2019

    Recent study finds dapagliflozin improves heart failure outcomes...

    READ
  • Self-care
    OTC Medicines Corner...
    November 12, 2019

    Topical capsaicin may be an option for severe vomiting...

    READ
  • ID/Cancers
    Infectious Diseases...
    November 5, 2019

    Fluoroquinolone use is decreasing, apparently because of safety...

    READ
  • Neuro/Psych
    Psychiatry...
    November 5, 2019

    Study says long-term use of methylphenidate for ADHD remains...

    READ
  • GI/Kidneys
    Gastroenterology...
    October 29, 2019

    H. pylori treatment and dietary supplements associated with...

    READ
  • Read more about FDA approves voxelotor for sickle cell disease
  • Read more about As-needed corticosteroid–beta-agonist inhalers for adults with mild to moderate asthma?
  • Read more about Survey suggests overuse of aspirin for primary prevention of CVD
  • Read more about Triple therapy in a single inhaler improves asthma symptoms and control, studies show
  • Read more about Analysis suggests OTC oral contraceptives may improve access, reduce unintended pregnancies
  • Read more about Riluzole oral film approved for patients with ALS
  • Read more about Acalabrutinib now approved for treatment of adults with CLL, SLL
  • Read more about Adalimumab-afzb, biosimilar to Humira, approved for multiple inflammatory conditions
  • Read more about FDA approves cenobamate tablets for adults with partial-onset seizures
  • Read more about Cefiderocol approved to treat complicated urinary tract infections

Pages

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • next ›
  • last »

Medication Monitor

NEW DRUG APPROVALS

  • December 2, 2019
    Voxelotor
    (Oxbryta):
    FDA approves voxelotor for sickle cell disease
  • November 26, 2019
    Cenobamate
    (Xcopri):
    FDA approves cenobamate tablets for adults with partial-onset seizures
See more New Drug Approvals

SUPPLEMENTAL APPROVALS

  • November 26, 2019
    Riluzole oral film
    (Exservan):
    Riluzole oral film approved for patients with ALS
  • November 26, 2019
    Acalabrutinib
    (Calquence):
    Acalabrutinib now approved for treatment of adults with CLL, SLL
See more Supplemental Approvals

ALERTS AND RECALLS

  • September 26, 2019
    Palbociclib, ribociclib, abemaciclib
    (Ibrance, Kisqali, Verzenio):
    FDA warns of breast cancer drugs that may cause severe lung inflammation
See more Alerts and Recalls

PRODUCT WITHDRAWALS

  • March 26, 2018
    Daclizumab
    (Zinbryta):
    Daclizumab withdrawn after reports of serious inflammatory brain disorders
See more Product withdrawals


                                

Editor's Picks

  • Survey suggests overuse of aspirin for primary...
  • Triple therapy in a single inhaler improves...
  • Analysis suggests OTC oral contraceptives may...
  • Non-TNFi biologics may be more effective than...
  • CDC publishes updated HPV vaccination...

Popular Articles

  • Another negative trial for vitamin D...
  • Quetiapine prescribing decreased after clinicians...
  • New data support apixaban over rivaroxaban for...
  • Aspirin may be good for knee replacement...
  • ASH releases new VTE guidelines

Popular Sections

  • Alerts and Recalls
  • Supplemental Approvals
  • New Drug Approvals
  • Cardiology
  • Alternative Medicines Corner

2215 Constitution Avenue NW, Washington, DC 20037 Telephone 202-628-4410 Fax 202-783-2351

© 2013 American Pharmacists Association All Rights Reserved.

About the American
Pharmacists Association

The American Pharmacists Association (APhA) is the organization whose members are recognized in society as essential in all patient care settings for optimal medication use that improves health, wellness and quality of life. Through information, education and advocacy, APhA empowers its members to improve medication use and advance patient care.

More info

About APhA DrugInfoLine

APhA DrugInfoLine (ISSN 2162-3015) is a weekly publication of, and is owned and copyrighted by the American Pharmacists Association, the national professional society of pharmacists. Materials in APhA DrugInfoLine do not neccessarily represent the policy, recommendations, or endorsement of APhA. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that the information contained in APhA DrugInfoLine is accurate and current; however, they shall have no ability to any person or entity with regard to claims, losses, or damage caused or alleged to be caused, directly or indirectly by use of any information contained in the publication. All decisions about drug therapy must be based on independent judgement of the clinician.

  • Contact Us
  • Section Advisors
  • Terms of Use
  • Privacy Policy